This solicited literature case was identified on 28-OCT-2013 via an article: Dorff TB, Tsao-Wei DD, Groshen S, 
Boswell W, Goidkom A, Xiong S, et al. Efficacy of Oxaliplatin Plus Pemetrexed in Chemotherapy Pretreated 
Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2013. Available from: 
http://dx.dolorg/10.1016/j.cigc.2013.07.011.  
This case concerns an elderly male patient of unknown age who developed pleural effusion unspecified time after 
starting oxaliplatin, pemetrexed. 
The aim of the study was to evaluate oxaliplatin plus pemetrexed (Pem0x) in men with metastatic castration-
resistant prostate cancer (CRPC) previously treated with a taxane to determine the clinical response rate, as well 
as pain palliation, progression-free survival, and overall survival (OS). 
Patient had no history of greater than or equal to grade 2 peripheral neuropathy. Concomitant medications included 
folic acid (Folate), cyanocobalamin (vitamin B12), and dexamethasone before and after treatment. No medical 
history or past drug was reported. 
On an unknown date, the patient commenced treatment with intravenous oxaliplatin at a dose 120 mg/m2 followed 
by intravenous pemetrexed at a dose 500 mg/rn2 both every three weeks (form, expiry date and lot no. unknown) 
both taken for metastatic castration resistant prostate cancer. 
On unknown date, the patient experienced pleural effusion with shortness of breath after 6 cycles of oxaliplatin and 
pemetrexed. 
The therapy with oxaliplatin, pemetrexed was discontinued. 
The event outcome of pleural effusion was unknown.